Eosinophilic pneumonia

Summary

Eosinophilic pneumonia (MONDO:0005749) is a disease and 4 clinical trials. Top therapeutic interventions include prednisolone. A subtype of pneumonia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	eosinophilic pneumonia
Mondo ID	MONDO:0005749
EFO	EFO:0007257
DOID	DOID:5870
NCIT	C35150
UMLS	C1527407
MedGen	282904
GARD	0027348
Is cancer (heuristic)	no

Also known as: eosinophilic pneumonia

Disease family

This is a subtype of pneumonia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › respiratory tract infectious disorder › pneumonia › eosinophilic pneumonia

Related subtypes (10): pleuropneumonia, idiopathic interstitial pneumonia, bacterial pneumonia, bronchopneumonia, contagious pleuropneumonia, recurrent pneumonia, viral pneumonia, pneumocystosis, acute fibrinous and organizing pneumonia, bronchiolocentric pattern of interstitial pneumonia

Subtypes (2): chronic eosinophilic pneumonia, idiopathic eosinophilic pneumonia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

3 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Dexamethasone	Approved (phase 4)
Prednisolone	Approved (phase 4)
Prednisone	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00632554	PHASE4	COMPLETED	The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia
NCT04538937	Not specified	RECRUITING	Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils
NCT01152424	Not specified	UNKNOWN	Usefulness of Exhaled NO in the Differential Diagnosis Acute Eosinophilic Pneumonia and Bacterial Pneumonia
NCT04671446	Not specified	COMPLETED	Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PREDNISOLONE	4	1